Abpro Holdings Inc. (ABPO)
OTC PINK OTC PINK Primary Summary
Abpro Holdings Inc. (ABPO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Abpro Holdings Inc. ever had a stock split?
Abpro Holdings Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jin Wook Suk CEO | OTC PINK Exchange | 000847202 CUSIP |
| US Country | 3 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Abpro Holdings, Inc. is a biotechnology company that specializes in developing innovative antibody constructs aimed at advancements in immuno-oncology and ophthalmology. The company leverages its proprietary platforms, DiversImmune and MultiMab, to create a diverse array of antibodies. DiversImmune is a discovery platform that enables the generation of a wide spectrum of proprietary antibodies targeting both clinically validated and novel targets. MultiMab serves as an engineering platform that allows for the combination of antibody building blocks in various configurations, resulting in purpose-built full-length multi-specific antibody constructs.
Products and Services
- ABP-102
ABP-102 is a next-generation immuno-oncology TetraBi antibody specifically designed to target HER2 and CD3. It is under development for the treatment of HER2+ solid tumors, including breast and gastric cancers.
- ABP-201
This TetraBi antibody format is engineered to simultaneously inhibit VEGF and ANG-2, making it a promising candidate for treating vascular diseases of the eye, such as diabetic macular edema and wet age-related macular degeneration.
- ABP-110
ABP-110 is a TetraBi antibody that targets both GPC3 and CD3, focused on providing therapeutic benefits for patients suffering from hepatocellular carcinoma.
- ABP-150
This TetraBi antibody targets claudin 18.2 and CD3, and is being developed for the treatment of gastric cancers, demonstrating Abpro's commitment to addressing critical medical needs.
